论文部分内容阅读
案情简介 大陆B公司系大陆C公司的原始股东,大陆B公司在2002年11月与台商A公司签订股权认购合同,约定A公司以156万美元购入大陆C公司60％的股权(大陆C公司资本260万美元),拟从事中药生物高科技方面的投资与开发。2002年12月在大陆B公司确认大陆C公司260万美元尚在公司帐上后,A公司于2002年12月20日将购买C公司股份款156万美元汇给大陆C公司。之后在
Brief introduction of the case Mainland B Company is the original shareholder of mainland C company, mainland company B in November 2002 with Taiwan’s A company signed a share subscription agreement, A company agreed to 1.56 million US dollars to buy a 60% stake in mainland C (mainland C Company capital 2.6 million US dollars), to be engaged in high-tech biological Chinese medicine investment and development. In December 2002, after mainland company B confirmed that mainland C company 2.6 million was still on the company’s account, company A remitted $ 1.56 million of shares of company C to mainland C on December 20, 2002. After that